Implementing Curcumin in Translational Oncology Research

Most data published on curcumin and curcumin-based formulations are very promising. In cancer research, the majority of data has been obtained in vitro. Less frequently, researchers used experimental animals. The results of several clinical studies are conclusive, and these studies have established...

Full description

Saved in:
Bibliographic Details
Published in:Molecules (Basel, Switzerland) Switzerland), 2020-11, Vol.25 (22), p.5240
Main Authors: Trošelj, Koraljka Gall, Samaržija, Ivana, Tomljanović, Marko, Kujundžić, Renata Novak, Đaković, Nikola, Mojzeš, Anamarija
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents - therapeutic use
Biological Availability
cancer therapy
clinical trials
Clinical Trials as Topic
Curcumin - chemistry
Curcumin - therapeutic use
Gastrointestinal Microbiome
Humans
IL-17
Interleukin-17 - chemistry
Medical Oncology - trends
metabolic reprogramming
microbiota
National Institutes of Health (U.S.)
Neoplasms - drug therapy
nicotinamide N-methyltransferase
Nicotinamide N-Methyltransferase - chemistry
Precision Medicine
Review
Translational Research, Biomedical - trends
United States
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Most data published on curcumin and curcumin-based formulations are very promising. In cancer research, the majority of data has been obtained in vitro. Less frequently, researchers used experimental animals. The results of several clinical studies are conclusive, and these studies have established a good foundation for further research focusing on implementing curcumin in clinical oncology. However, the issues regarding timely data reporting and lack of disclosure of the exact curcumin formulations used in these studies should not be neglected. This article is a snapshot of the current status of publicly available data on curcumin clinical trials and a detailed presentation of results obtained so far with some curcumin formulations. Phenomena related to the observed effects of curcumin shown in clinical trials are presented, and its modifying effect on gut microbiota and metabolic reprogramming is discussed. Based on available data, there is a strong indication that curcumin and its metabolites present molecules that do not necessarily need to be abundant in order to act locally and benefit systemically. Future clinical studies should be designed in a way that will take that fact into consideration.
ISSN:1420-3049
1420-3049
DOI:10.3390/molecules25225240